ICON plc is a global full service clinical research organisation. The company provides contract clinical research services to the pharmaceutical industry worldwide.
| Revenue (Most Recent Fiscal Year) | $8.25B |
| Net Income (Most Recent Fiscal Year) | $229.34M |
| PE Ratio (Current Year Earnings Estimate) | 18.00 |
| PE Ratio (Trailing 12 Months) | 17.95 |
| PEG Ratio (Long Term Growth Estimate) | 7.14 |
| Price to Sales Ratio (Trailing 12 Months) | 1.60 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.24 |
| Pre-Tax Margin (Trailing 12 Months) | 1.31% |
| Net Margin (Trailing 12 Months) | 3.99% |
| Return on Equity (Trailing 12 Months) | 8.02% |
| Return on Assets (Trailing 12 Months) | 4.56% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.95 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.23 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $122.48 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.35 |
| Earnings per Share (Most Recent Fiscal Year) | $11.48 |
| Diluted Earnings per Share (Trailing 12 Months) | $4.26 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 76.57M |
| Free Float | 42.88M |
| Market Capitalization | $13.21B |
| Average Volume (Last 20 Days) | 0.85M |
| Beta (Past 60 Months) | 1.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 44.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.61% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |